CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can help adults whose chronic lymphocytic leukemia (CLL) has returned after an earlier successful treatment. About 75 participants will receive the drugs in cycles over 12 to 24 months. Resea…

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The treatment uses specially modified cells to target a protein cal…

This study tests whether combining two targeted drugs, zanubrutinib and venetoclax, can deeply suppress chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people whose cancer returned after prior treatment. About 45 adults who have not used these specific d…

This study tests whether a combination of three drugs (zanubrutinib, obinutuzumab, and venetoclax) can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) undetectable in the body. About 230 adults who have not had prior treatment for these blood cancers w…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests a drug called venetoclax in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 110 participants will receive the drug to see if it shrinks their cancer. The goal is to…

This study tests an experimental drug called NX-5948 (bexobrutideg) in about 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding after treatment with BTK and BCL-2 inhibitors. The main goal is to see how many …

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. About 106 adults will take part.

This study is a registry that collects information from about 2,950 adults with certain blood cancers (like CLL, DLBCL, and others) in Germany. Researchers will track what treatments patients receive, how well they work, and how patients feel over time. No new drugs or treatments…

This study watches how certain blood cancer drugs (BTK inhibitors or venetoclax) affect the heart's rhythm. About 135 adults with cancers like CLL or mantle cell lymphoma will have heart tests before and during treatment. The goal is to spot dangerous heart rhythms early and unde…

This study looks back at medical records of 350 people with chronic lymphocytic leukemia (CLL) who received acalabrutinib through a UK early access program. Researchers want to see how long patients go without their cancer worsening and how long they live. The goal is to understa…

This early-phase study looks at how the drug pirtobrutinib changes immune cells in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 30 adults will take pirtobrutinib daily and have blood and lymph node tests to track immune syste…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers aim to use these samples to develop immunotoxins—a new type of drug that delivers a toxin directly to can…

This study follows 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for 2 years to see how their quality of life, fatigue, and symptoms change during treatment. Researchers compare two common treatment types to help future patients know what …

This study follows 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax alone or with other drugs as part of their normal treatment. Researchers will track how well the cancer responds, side effects, and costs. The goal is to see how the drug performs outs…